Riccardo Bruna
YOU?
Author Swipe
View article: Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy
Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy Open
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL) worldwide. Currently, approximately sixty percent of patients are cured with R-CHOP as frontline treatment, while the remaining patients experie…
View article: 154 | CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA
154 | CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA Open
View article: 277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI
277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI Open
View article: Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels Open
Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and ti…
View article: Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination Open
CLL patients face increased vulnerability to COVID-19 because of weakened immune systems from comorbidities and treatments. Therefore, the need for these patients of vaccination is of outermost importance. In our study we have evaluated T …
View article: IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma Open
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis irradi…
View article: New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Open
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. Approximately 60% of patients are cured with R-CHOP as a frontline treatment, while the remaining patients experience primary refractory or relapsed disease (R/R…
View article: Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry Open
View article: Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study Open
Introduction: Patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) have poor outcome. Time to first relapse or progression (POD) has been consistently shown to be an independent predictor of survival, with patients experie…
View article: MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRATIFICATION OF DLBCL PATIENTS COMPARED TO CTDNA LEVELS
MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRATIFICATION OF DLBCL PATIENTS COMPARED TO CTDNA LEVELS Open
Introduction: The quantification of circulating tumor DNA (ctDNA) on the liquid biopsy at the time of diagnosis allows to stratify the outcome of diffuse large B-cell lymphoma (DLBCL) patients but its integration with molecular clustering …
View article: Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL Open
The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients with mantle cel…
View article: Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
Supplementary Tables and Figures
View article: Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
Supplementary Tables and Figures
View article: Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncologic features to severity and mortality from COVID-19 and little guidance as …
View article: Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncologic features to severity and mortality from COVID-19 and little guidance as …
View article: SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry Open
View article: Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study Open
The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a his…
View article: SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia
SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia Open
Summary Little is known of the course of COVID‐19 and the antibody response to infection or vaccination in patients with hairy‐cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostl…
View article: Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients Open
Although chemotherapy (CHT) exposure is an established cause of telomere attrition, determinants of telomere length (TL) dynamics after chemotherapy are poorly defined. In this study, we analyzed granulocyte telomere dynamics in 34 adult l…
View article: Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group Open
Introduction. A number of recent studies have described outcomes of patients (pts) with hematological malignancies affected by SARS-CoV-2, however data according to a particular tumour type and its specific treatments are lacking. Aggressi…
View article: Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy Open
After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Nam…
View article: SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort Open
COVID‐19, the disease caused by SARS‐CoV‐2, is still afflicting thousands of people across the globe. Few studies on COVID‐19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian He…
View article: Induction of robust humoral immunity against <scp>SARS‐CoV</scp>‐2 after vaccine administration in previously infected haematological cancer patients
Induction of robust humoral immunity against <span>SARS‐CoV</span>‐2 after vaccine administration in previously infected haematological cancer patients Open
The coronavirus disease 2019 (COVID-19) is an ongoing, global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Impaired seroconversion has been repeatedly reported in patients with haematological malignancie…
View article: Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group
Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group Open
Summary To optimise management of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection identifying high‐risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. I…
View article: Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for <scp>COVID</scp>‐19: The <scp>GIMEMA EMATO</scp>‐0321 study
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for <span>COVID</span>‐19: The <span>GIMEMA EMATO</span>‐0321 study Open
Summary COVID‐19 continues to be a relevant issue among patients with haematological malignancies (HM). Vaccines are frequently not effective in subjects on active treatment. In this multicentre retrospective study of Gruppo Italiano Malat…
View article: Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study Open
View article: Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer Open
View article: Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry Open
View article: COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry Open
Background Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post–COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequela…
View article: Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients Open